While the overall risk appears to be small, I now screen more carefully for patients with risk factors such as pre-existing optic nerve problems, glaucoma, or significant diabetic retinopathy. Recent research also connects liraglutide, the active ingredient in Saxenda and Victoza, to similar concerns
TelX clinical oversight (board-certified, all 50 states)
Cost Per Pound Lost: Value Comparison The bottom line question: is the cost justified by results
Competitive Landscape : If approved, CT-388 would likely join other GLP-1 receptor agonists and various combination therapies on the market
Please Note: Once the product has been shipped, all sales are final and no refunds will be issued
Combination therapy has several potential advantages, including (1) increased durability of the glycaemic effect [225,226,227], addressing therapeutic inertia, (2) simultaneous targeting of the multiple pathophysiological processes characterised by type 2 diabetes, (3) impacts on medication burden, medication-taking behaviour and treatment persistence and (4) complementary clinical benefits (e.g